NASDAQ:ENTA Enanta Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enanta Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $44.83 +0.68 (+1.54 %) (As of 09/29/2020 12:00 AM ET) Add Compare Share Today's Range$43.88Now: $44.83▼$45.0650-Day Range$43.36MA: $47.81▼$52.1952-Week Range$38.40Now: $44.83▼$67.88Volume118,628 shsAverage Volume193,048 shsMarket Capitalization$899.83 millionP/E Ratio560.45Dividend YieldN/ABeta0.4 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.83, Enanta Pharmaceuticals has a forecasted upside of 58.0% from its current price of $44.83.Amount of Analyst CoverageEnanta Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesEnanta Pharmaceuticals has received 284 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEnanta Pharmaceuticals has received 332 “underperform” votes. (Add your “underperform” vote.)Community SentimentEnanta Pharmaceuticals has received 53.90% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote “Outperform” if you believe ENTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.93% of the stock of Enanta Pharmaceuticals is held by insiders.Percentage Held by Institutions90.19% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to decrease in the coming year, from ($0.68) to ($3.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is 560.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.56.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is 560.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.08.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.53 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA Previous Symbol CUSIPN/A CIK1177648 Webwww.enanta.com Phone617-607-0800Debt Debt-to-Equity RatioN/A Current Ratio17.29 Quick Ratio17.29Price-To-Earnings Trailing P/E Ratio560.45 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$205.20 million Price / Sales4.39 Cash Flow$2.17 per share Price / Cash Flow20.62 Book Value$23.50 per share Price / Book1.91Profitability EPS (Most Recent Fiscal Year)$2.21 Net Income$46.38 million Net Margins1.57% Return on Equity0.49% Return on Assets0.47%Miscellaneous Employees113 Outstanding Shares20,072,000Market Cap$899.83 million Next Earnings Date11/19/2020 (Estimated) OptionableOptionable $44.83 +0.68 (+1.54 %) (As of 09/29/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ENTA News and Ratings via Email Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions How has Enanta Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)? Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ENTA shares have decreased by 15.3% and is now trading at $44.83. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Enanta Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Enanta Pharmaceuticals. When is Enanta Pharmaceuticals' next earnings date? Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 19th 2020. View our earnings forecast for Enanta Pharmaceuticals. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals Inc (NASDAQ:ENTA) announced its quarterly earnings data on Tuesday, August, 4th. The biotechnology company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The biotechnology company had revenue of $18.70 million for the quarter, compared to analysts' expectations of $25.47 million. Enanta Pharmaceuticals had a return on equity of 0.49% and a net margin of 1.57%. The firm's quarterly revenue was down 57.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 earnings per share. View Enanta Pharmaceuticals' earnings history. What price target have analysts set for ENTA? 6 equities research analysts have issued 1 year price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $49.00 to $104.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $70.83 in the next twelve months. This suggests a possible upside of 58.0% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals. Who are some of Enanta Pharmaceuticals' key competitors? Some companies that are related to Enanta Pharmaceuticals include Insmed (INSM), Principia Biopharma (PRNB), TG Therapeutics (TGTX), Global Blood Therapeutics (GBT), HYPERA S A/S (HYPMY), PTC Therapeutics (PTCT), Reata Pharmaceuticals (RETA), SAGE Therapeutics (SAGE), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR), Schrodinger (SDGR), Deciphera Pharmaceuticals (DCPH), Axsome Therapeutics (AXSM), Alkermes (ALKS) and Pacira Biosciences (PCRX). View all competitors. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals PLC- (GWPH), Micron Technology (MU) and Zoetis (ZTS). Who are Enanta Pharmaceuticals' key executives? Enanta Pharmaceuticals' management team includes the following people: Dr. Jay R. Luly, Pres, CEO & Director (Age 63)Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 64)Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 67)Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 65)Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 53) What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $44.83. How big of a company is Enanta Pharmaceuticals? Enanta Pharmaceuticals has a market capitalization of $899.83 million and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe. What is Enanta Pharmaceuticals' official website? The official website for Enanta Pharmaceuticals is www.enanta.com. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected] This page was last updated on 9/29/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
